0      0


JL1102ES - JL1102ES: Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non-small cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS


‐ Oct 26, 2023 8:00pm

Se-Hoon Lee,1 Byoung Chul Cho,2 Ji-Youn Han,3 Eun Kyung Cho,4 Jong-Seok Lee,5 Ki Hyeong Lee,6 Joshua C. Curtin,7 Grace Gao,8 John Xie,9 Robert W. Schnepp,7 Joshua M. Bauml,7 Roland E. Knoblauch,7 Meena Thayu,7 Dong-Wan Kim10

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; 3National Cancer Center, Goyang-Si, Republic of Korea; 4Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea; 5Seoul National University Bundang Hospital, Seongnam, Republic of Korea; 6Chungbuk National University Hospital, Cheongju, Republic of Korea; 7Janssen R&D, Spring House, PA, USA; 8Janssen China R&D, Shanghai, China; 9Janssen R&D, Raritan, NJ; 10Seoul National University Hospital, Seoul, Republic of Korea



Presenter(s):

You must be logged in and own this session in order to post comments.